Omeros Corporation (NASDAQ:OMER) – Investment analysts at Wedbush decreased their FY2016 earnings per share (EPS) estimates for Omeros Corporation in a research note issued to investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the firm will post earnings of ($1.52) per share for the year, down from their previous forecast of ($1.33). Wedbush currently has a “Outperform” rating and a $47.00 price objective on the stock. Wedbush also issued estimates for Omeros Corporation’s Q4 2016 earnings at ($0.34) EPS, Q1 2017 earnings at ($0.34) EPS, Q2 2017 earnings at ($0.28) EPS, Q3 2017 earnings at ($0.19) EPS, Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.90) EPS, FY2018 earnings at $0.61 EPS, FY2019 earnings at $2.02 EPS and FY2020 earnings at $3.65 EPS.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. The firm had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $11.64 million. During the same period in the prior year, the company earned ($0.53) EPS. The firm’s quarterly revenue was up 253.1% on a year-over-year basis.

Earnings History and Estimates for Omeros Corporation (NASDAQ:OMER)

Several other analysts also recently issued reports on OMER. Maxim Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Omeros Corporation in a report on Thursday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price target on shares of Omeros Corporation in a report on Wednesday, August 10th. Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, October 12th. S&P Equity Research upped their price target on shares of Omeros Corporation from $7.65 to $8.63 in a report on Monday, October 17th. Finally, WBB Securities reaffirmed a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a report on Monday, October 17th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.23.

Omeros Corporation (NASDAQ:OMER) opened at 13.07 on Friday. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $16.80. The stock’s 50 day moving average price is $9.53 and its 200-day moving average price is $10.84. The stock’s market cap is $560.90 million.

In related news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the transaction, the vice president now owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.60% of the company’s stock.

A number of institutional investors have recently modified their holdings of the company. D.A. Davidson & CO. raised its position in shares of Omeros Corporation by 2.9% in the third quarter. D.A. Davidson & CO. now owns 270,245 shares of the biopharmaceutical company’s stock valued at $3,015,000 after buying an additional 7,723 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of Omeros Corporation during the third quarter valued at approximately $144,000. D. E. Shaw & Co. Inc. raised its position in shares of Omeros Corporation by 16.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 431,339 shares of the biopharmaceutical company’s stock valued at $4,813,000 after buying an additional 60,954 shares during the period. Virtus ETF Advisers LLC raised its position in shares of Omeros Corporation by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 55,936 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 7,049 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Omeros Corporation during the third quarter valued at approximately $2,734,000. 51.86% of the stock is owned by hedge funds and other institutional investors.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.